Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of ˃20,000 patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tabrizian, Parissa | - |
dc.contributor.author | Saberi, Behnam | - |
dc.contributor.author | Holzner, Matthew L. | - |
dc.contributor.author | Rocha, Chiara | - |
dc.contributor.author | Jung, Yun Kyung | - |
dc.contributor.author | Myers, Bryan | - |
dc.contributor.author | Florman, Sander S. | - |
dc.contributor.author | Schwartz, Myron E. | - |
dc.date.accessioned | 2023-08-16T07:58:56Z | - |
dc.date.available | 2023-08-16T07:58:56Z | - |
dc.date.created | 2023-07-21 | - |
dc.date.issued | 2022-07 | - |
dc.identifier.issn | 1365-182X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/189215 | - |
dc.description.abstract | Background: The development of direct-acting antiviral (DAA) therapy has revolutionized HCV management. We present a large national study comparing post-LT outcomes for HBV-HCC vs. HCV-HCC according to DAA era.Methods: Data were collected from OPTN/UNOS Registry. Groups included pre-DAA (January 2003-October 2013) and post-DAA (November2013-January2019) eras. Outcomes for patients with HBV(n = 2000) vs. HCV(n = 18,964) were compared in each era. Results: In the pre-DAA era, there were significant differences between HBV-versus HCV, including the percentage of Caucasian race, pre-LT and maximum AFP levels <20 ng/mL, MELD-score, complete tumor necrosis, and vascular invasion. In the post-DAA-era, differences were noted in wait time>9 months, the percentage of Caucasian race, pre-LT and AFP(max) levels<20 ng/mL, and MELD-score. In the pre-DAA-era, the 5-and-10 year survival rates were 80.5% and 71% for HBV-HCC, and 69% and 54.4% for HCV-HCC (p < 0.001); in the post-DAA-era, 5-year survival was 83.4% for HBV-HCC and 78.5% for HCV-HCC(p = 0.08). Independent pre-LT predictors of lower survival included recipient and donor age>50yrs, wait-time>9months, higher MELD-score (p < 0.001), AFP level>20 ng/mL, and MC at diagnosis. HCV status did not predict outcome in the post-DAA-era after adjusting for tumor characteristics.Conclusion: After the introduction of effective DAA-HCV therapy, results of LT for HCV-HCC are significantly improved and are no longer statistically different from results in patients with HBV-HCC. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of ˃20,000 patients | - |
dc.title.alternative | Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of >20,000 patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Yun Kyung | - |
dc.identifier.doi | 10.1016/j.hpb.2021.11.018 | - |
dc.identifier.scopusid | 2-s2.0-85121829725 | - |
dc.identifier.wosid | 000822922100010 | - |
dc.identifier.bibliographicCitation | HPB, v.24, no.7, pp.1082 - 1090 | - |
dc.relation.isPartOf | HPB | - |
dc.citation.title | HPB | - |
dc.citation.volume | 24 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1082 | - |
dc.citation.endPage | 1090 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | HEPATITIS-C | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1365182X21017238 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.